Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a challenging third quarter for fiscal year 2014, with a net loss of $12.8 million, or $0.06 per diluted share, compared to a net income of $168.4 million in the prior year quarter. This downturn was largely driven by a significant increase in warrant expense related to their strategic relationship with Walgreens and Alliance Boots, as well as higher LIFO expense and a loss on early debt retirement. Despite the quarterly loss, the nine-month period showed a net income of $208.7 million, though down from $382.7 million in the prior year. Revenue demonstrated strong growth, increasing by 38.5% year-over-year for the quarter to $30.3 billion, primarily due to the continued ramp-up of the distribution agreement with Walgreens. However, the pharmaceutical distribution segment's gross profit margin declined due to a higher mix of lower-margin brand business and competitive pressures. Investors should note the significant increase in debt, particularly the issuance of new senior notes, to facilitate debt retirement and general corporate purposes, including share repurchases. The company is actively managing the potential dilutive effects of warrants through hedging strategies and share repurchases. While the top-line revenue growth is positive, the impact of the warrant expense and margin pressures on profitability remains a key focus for investors in the near term. The company also faces ongoing legal proceedings and investigations, particularly concerning controlled substance diversion, which could have future financial implications.
Financial Highlights
54 data points| Revenue | $30.35B |
| Cost of Revenue | $29.66B |
| Gross Profit | $692.00M |
| SG&A Expenses | $387.61M |
| Operating Income | $110.88M |
| Net Income | -$12.78M |
| EPS (Basic) | $-0.06 |
| EPS (Diluted) | $-0.06 |
| Shares Outstanding (Basic) | 225.73M |
| Shares Outstanding (Diluted) | 225.73M |
Key Highlights
- 1Reported a net loss of $12.8 million for the quarter ended June 30, 2014, a significant decline from a net income of $168.4 million in the prior year quarter, primarily due to increased warrant and LIFO expenses.
- 2Revenue surged by 38.5% to $30.3 billion, driven by the ongoing integration and growth of the Walgreens distribution agreement.
- 3The Pharmaceutical Distribution segment, the company's largest, saw revenue increase by 39.3%, but its gross profit margin decreased due to a higher volume of lower-margin business and competitive pressures.
- 4Long-term debt increased substantially, with the issuance of $1.1 billion in new senior notes to refinance existing debt and for general corporate purposes, including share repurchases.
- 5The company is actively mitigating the dilutive impact of outstanding warrants through hedging transactions (capped calls) and share repurchase programs.
- 6Continued legal proceedings and investigations, particularly related to controlled substance diversion, pose potential ongoing risks.
- 7The company's effective tax rate significantly increased to 121.9% for the quarter due to the non-deductible nature of a large portion of warrant expense.